Coologics, a clinical-stage medical device company, announced the closing of a seed funding round. This round was oversubscribed, showing strong investor confidence in Coologics’ vision and technology around its initial product, Vlisse.
The seed funding round secured $3+ million in investment, exceeding the initial target of $1.5 million. This funding round was led by Prevail and Dream Ventures and saw material participation from two university alumni groups: Ohio State Early Investor Network and Illinois Ventures Illini Angels Program. The company’s CEO/founder, Dr. Kim Langdon, and Chief Medical Officer, Dr. Nicole Williams, are alumni of Ohio State University and the University of Illinois, respectively.
This significant funding round will be instrumental in accelerating Coologics’ key milestones, around the completion of their ongoing clinical trial, FDA submission and initial market release of their flagship product, Vlisse.
Coologics is committed to supporting female health and treating the underlying issues affecting women daily. And the completion of this seed round marks a major step forward in realizing this vision and bringing Vlisse to market.
KEY QUOTES:
“We are beyond excited about the investor commitment to Coologics. The overwhelming interest in our seed round validates the critical need for a more effective treatment for vaginal infections. We are thrilled to welcome our new investors and leverage their expertise to accelerate our growth and deliver impactful solutions to female patients and their clinicians.”
Dr. Langdon, CEO/Founder
“Dr. Langdon’s vision and passion for this problem is what excited us the most about Coologics. This market is ripe for innovative solutions like Vlisse. I look forward to watching our experienced teams at Prevail and Dream strategically support Coologics efforts in bringing Vlisse to market.”
Kerry Lawing, Prevail Ventures CEO
